Suppr超能文献

继发性甲状旁腺功能亢进和移植后三发性甲状旁腺功能亢进的治疗。

Treatment of Secondary Hyperparathyroidism and Posttransplant Tertiary Hyperparathyroidism.

作者信息

Egan Caitlin E, Qazi Murtaza, Lee Joyce, Lee-Saxton Yeon J, Greenberg Jacques A, Beninato Toni, Zarnegar Rasa, Fahey Thomas J, Finnerty Brendan M

机构信息

Department of Surgery, Weill Cornell Medicine, New York, New York.

Department of Surgery, Weill Cornell Medicine, New York, New York.

出版信息

J Surg Res. 2023 Nov;291:330-335. doi: 10.1016/j.jss.2023.06.031. Epub 2023 Jul 26.

Abstract

INTRODUCTION

Secondary hyperparathyroidism (sHPT) is prevalent in dialysis patients and can lead to tertiary hyperparathyroidism (tHPT) after kidney transplantation. We aimed to assess the association of pretransplant sHPT treatment on posttransplant outcomes.

METHODS

We reviewed kidney transplant patients treated with parathyroidectomy or cinacalcet for sHPT. We compared patients biochemical and clinical parameters, and outcomes based on sHPT treatment.

RESULTS

A total of 41 patients were included: 18 patients underwent parathyroidectomy and 23 patients received cinacalcet prior to transplantation. There were no significant differences between demographics, comorbidities, allograft characteristics or pre-sHPT intervention parathyroid hormone (PTH) and calcium levels. Patients that underwent parathyroidectomy were on dialysis for longer, although not significantly (71.9 versus 42.3 mo, P = 0.051). At time of transplantation, patients treated by parathyroidectomy had increased rates of controlled sHPT (88.9%; 16/18 versus 47.8%; 11/23, P = 0.008). Patients treated by parathyroidectomy had decreased development of tHPT (5.9%; 1/17; versus 42.1%; 8/19, P = 0.020) as well as decreased rates of posttransplant treatment with cinacalcet (11.1%; 2/18 versus 52.2%; 12/23, P = 0.008). Three patients treated with cinacalcet underwent parathyroidectomy after transplantation. Median PTH after transplant remained lower in patients treated by parathyroidectomy prior to transplant compared to those treated with cinacalcet (60.7 [interquartile range 39.7-133.4] versus 170.0 [interquartile range 128.4-292.7], P = 0.001). Allograft function and survival were similar for parathyroidectomy and cinacalcet, with median follow-up after transplantation of 56.7 and 34.2 mo, respectively.

CONCLUSIONS

sHPT treated by parathyroidectomy is associated with controlled PTH levels at transplantation and decreased rates of tHPT. Long-term outcomes should be studied on a larger scale.

摘要

引言

继发性甲状旁腺功能亢进(sHPT)在透析患者中很常见,并且在肾移植后可导致三发性甲状旁腺功能亢进(tHPT)。我们旨在评估移植前sHPT治疗与移植后结局之间的关联。

方法

我们回顾了接受甲状旁腺切除术或西那卡塞治疗sHPT的肾移植患者。我们比较了患者的生化和临床参数,以及基于sHPT治疗的结局。

结果

共纳入41例患者:18例患者接受了甲状旁腺切除术,23例患者在移植前接受了西那卡塞治疗。在人口统计学、合并症、同种异体移植物特征或移植前sHPT干预时的甲状旁腺激素(PTH)和钙水平方面,两组之间没有显著差异。接受甲状旁腺切除术的患者透析时间更长,尽管差异不显著(71.9个月对42.3个月,P = 0.051)。在移植时,接受甲状旁腺切除术治疗的患者sHPT得到控制的比例更高(88.9%;16/18对47.8%;11/23,P = 0.008)。接受甲状旁腺切除术治疗的患者tHPT的发生率降低(5.9%;1/17对42.1%;8/19,P = 0.020),并且移植后接受西那卡塞治疗的比例也降低(11.1%;2/18对52.2%;12/23,P = 0.008)。3例接受西那卡塞治疗的患者在移植后接受了甲状旁腺切除术。与接受西那卡塞治疗的患者相比,移植前接受甲状旁腺切除术治疗的患者移植后的PTH中位数仍然较低(60.7[四分位间距39.7 - 133.4]对170.0[四分位间距128.4 - 292.7],P = 0.001)。甲状旁腺切除术和西那卡塞治疗的同种异体移植物功能和存活率相似,移植后的中位随访时间分别为56.7个月和34.2个月。

结论

甲状旁腺切除术治疗的sHPT与移植时PTH水平得到控制以及tHPT发生率降低有关。应进行更大规模的长期结局研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验